Literature DB >> 19906907

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Ann J Hessell1, Eva G Rakasz, David M Tehrani, Michael Huber, Kimberly L Weisgrau, Gary Landucci, Donald N Forthal, Wayne C Koff, Pascal Poignard, David I Watkins, Dennis R Burton.   

Abstract

The membrane-proximal external region (MPER) of HIV-1, located at the C terminus of the gp41 ectodomain, is conserved and crucial for viral fusion. Three broadly neutralizing monoclonal antibodies (bnMAbs), 2F5, 4E10, and Z13e1, are directed against linear epitopes mapped to the MPER, making this conserved region an important potential vaccine target. However, no MPER antibodies have been definitively shown to provide protection against HIV challenge. Here, we show that both MAbs 2F5 and 4E10 can provide complete protection against mucosal simian-human immunodeficiency virus (SHIV) challenge in macaques. MAb 2F5 or 4E10 was administered intravenously at 50 mg/kg to groups of six male Indian rhesus macaques 1 day prior to and again 1 day following intrarectal challenge with SHIV(Ba-L). In both groups, five out of six animals showed complete protection and sterilizing immunity, while for one animal in each group a low level of viral replication following challenge could not be ruled out. The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906907      PMCID: PMC2812338          DOI: 10.1128/JVI.01272-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Antibody pharmacokinetics and pharmacodynamics.

Authors:  Evelyn D Lobo; Ryan J Hansen; Joseph P Balthasar
Journal:  J Pharm Sci       Date:  2004-11       Impact factor: 3.534

2.  Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.

Authors:  Zhi-Qiang Zhang; Tong-Ming Fu; Danilo R Casimiro; Mary-Ellen Davies; Xiaoping Liang; William A Schleif; Larry Handt; Lynda Tussey; Minchun Chen; Aimin Tang; Keith A Wilson; Wendy L Trigona; Daniel C Freed; Charles Y Tan; Melanie Horton; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

Authors:  Ranajit Pal; Brian Taylor; J Scott Foulke; Ruth Woodward; Michael Merges; Rob Praschunus; Andrew Gibson; Marvin Reitz
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

4.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

5.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

6.  Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Authors:  Bianca R Mothé; Jason Weinfurter; Chenxi Wang; William Rehrauer; Nancy Wilson; Todd M Allen; David B Allison; David I Watkins
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

Authors:  Michael B Zwick; H Kiyomi Komori; Robyn L Stanfield; Sarah Church; Meng Wang; Paul W H I Parren; Renate Kunert; Hermann Katinger; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.

Authors:  Flavia Ferrantelli; Robert A Rasmussen; Kathleen A Buckley; Pei-Lin Li; Tao Wang; David C Montefiori; Hermann Katinger; Gabriela Stiegler; Daniel C Anderson; Harold M McClure; Ruth M Ruprecht
Journal:  J Infect Dis       Date:  2004-05-26       Impact factor: 5.226

9.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

10.  Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Authors:  Ann J Hessell; Eva G Rakasz; Pascal Poignard; Lars Hangartner; Gary Landucci; Donald N Forthal; Wayne C Koff; David I Watkins; Dennis R Burton
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

View more
  207 in total

1.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 4.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

5.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

6.  International multicenter study to assess a panel of reference materials for quantification of simian immunodeficiency virus RNA in plasma.

Authors:  Claire Ham; Priya Srinivasan; Rigmor Thorstensson; Ernst Verschoor; Zahra Fagrouche; Leonardo Sernicola; Artur Ramos; Fausto Titti; Neil Almond; Neil Berry
Journal:  J Clin Microbiol       Date:  2010-04-28       Impact factor: 5.948

7.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

8.  Scaffolding to build a rational vaccine design strategy.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

9.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

10.  Non-Antiretroviral Microbicides for HIV Prevention.

Authors:  Yanille Scott; Charlene S Dezzutti
Journal:  AIDS Rev       Date:  2016 Jul-Sep       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.